Cited by 13Behavioral Health and InterventionsMaternal and Neonatal HealthcareHealthcare Policy and Management

Systematic review on use of health incentives in U.S. to change maternal health behavior

Open access
Washio, Yukiko, Atreyapurapu, Sravanthi, Hayashi, Yusuke, Taylor, Shantae, Chang, Katie, Ma, Tony, Isaacs, Krystyna·2021·Preventive Medicine

Abstract

Use of financial incentives contingent on health outcomes has shown effective in health behavior change. Evidence-based information on the effect of incentive use for maternal health behavior change can inform whether and how to proceed with future research as well as incorporate incentive-based interventions in the existing healthcare system. This systematic literature review was conducted among prospective studies on incentive use for maternal health behavior change in a U.S. cohort according to the PRISMA methodology. Databases subject to the search included PubMed, Web of Science, PsycINFO, and EBSCOhost. Studies published in peer-reviewed journals on or before January 7, 2019, written in English, conducted in U.S., using incentives contingent on maternal health behavior change, and prospectively designed were included. Two authors independently searched titles and abstracts. An abstraction table was constructed, and the risk of bias was assessed using the GRADE approach. The review showed that incentives such as vouchers and other financial incentives were effective in improving outcomes especially related to substance use, tobacco use, and breastfeeding. Mixed evidence was found in improving treatment adherence outcomes; however the studies with randomized trials on the outcome of treatment adherence also showed low certainty. Continued improvements need to be made in implementing an incentive-based approach in the context of comprehensive treatment and routine healthcare, exploring electronic- or mobile-based implementation of the approach, and implementing the approach for a wider variety of outcomes during both prenatal and postpartum periods.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ypmed.2021.106442

Cites

49 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Limited data indicate that alpha-2 adrenergic agonists (e.g., dexmedetomidine for severe symptoms, clonidine for mild to moderate symptoms) are beneficial for stimulant-induced agitation and can help with hypertension and tachycardia.

    “Limited data indicate that alpha-2 adrenergic agonists (eg, dexmedetomidine for more severe symptoms, clonidine for mild to moderate symptoms) are beneficial in treating stimulantinduced agitation and can also be useful in the treatment of hypertension and tachycardia and, thus, should be considered in the management of the hyperadrenergic state of stimulant intoxication.152,153”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [152]

    The Results section on pregnant and postpartum women with substance use disorders discusses vouchers for abstinence and treatment attendance, not medications for stimulant intoxication. Searches for alpha-2 adrenergic agonists, dexmedetomidine, clonidine, hypertension, tachycardia, and stimulant-induced agitation found no passage addressing the claim. (LLM, conf=0.75)

    Experimental — accuracy not yet measured
  • A 2015 review by Richards and colleagues identified six high-quality studies that support antipsychotics and benzodiazepines for agitation and psychosis.

    “Richards et al (2015) reviewed six high-quality studies supporting the use of antipsychotics and benzodiazepines to manage agitation and psychosis.152”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [152]

    Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Dexmedetomidine was reported to successfully treat cocaine-associated hypertensive emergencies, while propranolol, sodium nitroprusside, nifedipine, labetalol, and phentolamine were reported to successfully treat ATS-associated hypertensive emergencies.

    “All evidence came from case reports and case series; cocaine-associated hypertensive emergencies were successfully treated with dexmedetomidine, and ATS-associated hypertensive emergencies were successfully treated with propranolol, sodium nitroprusside, nifedipine, labetalol, and phentolamine.”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [152]

    Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • The evidence base for treating stimulant-associated hypertensive emergency consisted entirely of case reports and case series.

    “All evidence came from case reports and case series; cocaine-associated hypertensive emergencies were successfully treated with dexmedetomidine, and ATS-associated hypertensive emergencies were successfully treated with propranolol, sodium nitroprusside, nifedipine, labetalol, and phentolamine.”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [152]

    The Results (Synthesis of Results; no page provided) discuss incentives for maternal substance abstinence, not treatment of stimulant-associated hypertensive emergencies. Searches for case reports, case series, hypertensive emergencies, and the named drugs found no passage addressing the claim. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Two systematic reviews examined treatment for stimulant-associated hypertensive emergency.

    “Two systematic reviews were identified that examined treatment for stimulant-associated hypertensive emergency.152,153”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [152]

    The Study Selection and Results sections describe a systematic review of incentives for maternal health behaviors, including cocaine abstinence among pregnant and postpartum women. Neither those passages nor searches for stimulant-associated hypertensive emergency and its treatment address treatment of hypertensive emergencies. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Higgins Stephen T, Washio Y, Heil SH, Solomon LJ, Gaalema DE, Higgins TM, & Bernstein IM (2012). Financial incentives for smoking cessation among pregnant and newly postpartum women. Preventive Medicine, 55 Suppl, S33– 40. doi: 10.1016/j.ypmed.2011.12.016 22227223 PMC3399924 · DOI
  2. The National Institute for Health and Care Excellence. (2010). NICE Citizens Council meeting The use of incentives to improve health. 28230941

Cited by

Sorted by citations

Authors
Washio, Y., Atreyapurapu, S., Hayashi, Y., Taylor, S., Chang, K., Ma, T., & Isaacs, K.
Affiliations
  • RTI International (US)
  • Benten Technologies (United States) (US)
  • Pennsylvania State University (US)
Corresponding author
Washio, Yukiko
Venue
Preventive Medicine
Publisher
Elsevier BV
Published
2021-04
Volume
145
Pages
106442
ISSN
0091-7435 (ISSN-L)
OpenAlex
W3124352809
Cited by
13
References
48
Citations by year
2025: 3 · 2024: 1 · 2023: 5 · 2022: 4
FWCI
0.40
Type
journal article
Language
en
Open access
Locations
  • Preventive Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Topics
  • Social Sciences › Psychology › Applied Psychology › Behavioral Health and Interventions
  • Health Sciences › Health Professions › General Health Professions › Maternal and Neonatal Healthcare
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
Keywords
financial incentives, maternal health behavior, health behavior change, vouchers, substance use, tobacco use, breastfeeding, medication adherence, prenatal care, postpartum care, incentive-based interventions
MeSH terms
Breast Feeding, Delivery of Health Care, Female, Humans, Motivation, Pregnancy, Prospective Studies, Health Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review